Compare ATLO & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | NKTX |
|---|---|---|
| Founded | 1903 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.3M | 133.5M |
| IPO Year | N/A | 2020 |
| Metric | ATLO | NKTX |
|---|---|---|
| Price | $23.90 | $1.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 19.8K | ★ 643.0K |
| Earning Date | 01-23-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | ★ 82.57 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $60,568,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.22 | ★ N/A |
| Revenue Growth | ★ 18.60 | N/A |
| 52 Week Low | $15.75 | $1.31 |
| 52 Week High | $24.11 | $2.74 |
| Indicator | ATLO | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 81.63 | 48.81 |
| Support Level | $21.86 | $1.78 |
| Resistance Level | $22.30 | $1.90 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | 0.21 | 0.02 |
| Stochastic Oscillator | 90.91 | 75.00 |
Ames National Corporation is a United States-based bank holding company. It provides short-term and medium-term commercial, multi-family, and agricultural real estate loans, residential real estate loans, agricultural and business operating loans and lines of credit, equipment loans, vehicle loans, personal loans and lines of credit, home improvement loans and origination of mortgage loans for sale into the secondary market. The Banks also offer a variety of checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit and automated/video teller machine access. The banking segment generates revenues through personal, business, agricultural and commercial lending, and Others.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.